Cytokeratin 10 Antibody [SPM623] | 33-677

Cytokeratin 10 Antibody [SPM623] | 33-677 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human, Dog, Cat

Homology: N/A

Immunogen: A cytoskeletal preparation extracted from human ectocervical epithelium was used as the immunogen for the Cytokeratin 10 antibody.

Research Area: Signal Transduction

Tested Application: Flow, IF, IHC-P

Application: Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
Immunofluorescence: 0.5-1 ug/ml
Immunohistochemistry (FFPE) : 0.1-0.2 ug/ml for 30 min at RT
Optimal dilution of the Cytokeratin 10 antibody should be determined by the researcher.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Protein G affinity chromatography

Clonality: Monoclonal

Clone: SPM623

Isotype: IgG1, kappa

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: Keratin, type I cytoskeletal 10, Cytokeratin-10, CK-10, Keratin-10, K10, KRT10, KPP

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10) . CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III) , CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.